Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: A case-control study

Journal of Asthma

Volumn 51, Issue 10, 2014, Pages 1004-1013

  Raeiszadeh Jahromi, Sareh ^a   Mahesh, P A ^b   Jayaraj, B S ^b   Madhunapantula, Subba Rao V ^b   Holla, Amrutha D ^c   Vishweswaraiah, Sangeetha ^a   Ramachandra, Nallur B ^a  

^a UNIVERSITY OF MYSORE   (India)

^b JSS MEDICAL COLLEGE   (India)

^c Allergy Asthma and Chest Center   (India)

Author keywords

Biomarkers; Immunopathogenesis; Phenotype

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17F; INTERLEUKIN 33; BIOLOGICAL MARKER; IL17F PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; ASTHMA; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MALE; PROTEIN BLOOD LEVEL; BLOOD; IMMUNOLOGY; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; VITAL CAPACITY;

ADULT; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKINS; MALE; STATISTICS, NONPARAMETRIC; VITAL CAPACITY;

EID: 84910607900     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.938353     Document Type: Article

References (72)

1. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 30326:298-304.
2. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003;111: 450-463.
3. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program: the global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-478.
4. Barnes PJ. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 2003;14:511-522.
5. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-3556.
6. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002;42:81-98.
7. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human mono-cytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220.
8. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993;151:2390-2398.
9. Becker JC, Czerny C, Bröcker EB. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 1994;6:1605-1612.
10. Takanaski S, Nonaka R, Xing Z, O'Byrne P, Dolovich J, Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 1994;180:711-715.
11. Punnonen J, de Waal Malefyt R, van Vlasselaer P, Gauchat JF, de Vries JE. IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-1289.
12. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54: 825-857.
13. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23: 479-490.
14. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-978.
15. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007;40:216-225.
16. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179: 2051-2054.
17. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772-781.
18. John M, Au BT, Jose PJ, Lim S, Saunders M, Barnes PJ, Mitchell JA, et al. Expression and release of interleukin-8 by human airway smooth muscle cells: inhibition by Th-2 cyto-kines and corticosteroids. Am J Respir Cell Mol Biol 1998;18: 84-90.
19. Bernstein DI, Cartier A, Côté J, Malo JL, Boulet LP, Wanner M, Milot J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002;166:445-450.
20. Lummus ZL, Alam R, Bernstein JA, Bernstein DI. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol 1998;102:265-274.
21. Redington AE, Madden J, Frew AJ, Djukanovic R, Roche WR, Holgate ST, Howarth PH. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1997;156:642-647.
22. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004;114: 1265-1273.
23. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, et al. Interleukins, from 1 to 37, and interferon-g: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-721.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
25. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
26. Antunes J, Borrego L, Romeira A, Pinto P. Skin prick tests and allergy diagnosis. Allergol Immunopathol (Madr) 2009;37: 155-164.
27. Aas K, Belin L. Standardization of diagnostic work in allergy. Int Arch Allergy Appl Immunol 1973;45:57-60.
28. Kim CK, Kim SW, Park CS, Kim BI, Kang H, Koh YY. Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J Allergy Clin Immunol 2003;112:64-71.
29. Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010; 138:1140-1147.
30. Currie GP, Fardon TC, Lee DK. The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma. Ther Clin Risk Manag 2005;1:83-92.
31. Pukelsheim K, Stoeger T, Kutschke D, Ganguly K, Wjst M. Cytokine profiles in asthma families depend on age and phenotype. PLoS One 2010;5:e14299.
32. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol 2002;42:81-98.
33. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996;97:1288-1296.
34. Gupta A, Dimeloe S, Richards DF, Chambers ES, Black C, Urry Z, Ryanna K, et al. Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma. Thorax 2014;69:508-15.
35. John M, Lim S, Seybold J, Jose P, Robichaud A, O'Connor B, Barnes PJ, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998;157:256-262.
36. Liu M, Liu K, Zhu N, Xia J, Chen X. Inflammatory mediators in induced sputum and airway hyperresponsiveness in cough variant asthma during long-term inhaled corticosteroid treatment. Mediators Inflamm 2012;2012:403868.
37. Cao Y, Gong W, Zhang H, Liu B, Li B, Wu X, Duan X, et al. A comparison of serum and sputum inflammatory mediator profiles in patients with asthma and COPD. J Int Med Res 2012;40: 2231-2242.
38. Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL-10, TGF-b, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012; 2012:720976.
39. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001;125:177-183.
40. Ceyhan BB, Enc FY, Sahin S. IL-2 and IL-10 levels in induced sputum and serum samples of asthmatics. J Investig Allergol Clin Immunol 2004;14:80-85.
41. Stelmach I, Jerzyńska J, Bobrowska M, Brzozowska A, Majak P, Kuna P. IL-10 serum levels in children with moderate asthma. Pneumonol Alergol Pol 2002;70:25-33.
42. Yssel H, De Waal Malefyt R, Roncarolo MG, Abrams JS, Lahesmaa R, Spits H, de Vries JE. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 1992;149:2378-2384.
43. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, Liu MC, et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol 2001;167: 4430-4435.
44. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, Wang W, et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomo-dulatory activity. J Biol Chem 2000;275:19167-19176.
45. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205:1063-1075.
46. Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q. T (H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009;123: 1185-1187.
47. Kokubu F, Matsukura S, Kawaguchi M, Osakabe Y. Respiratory viruses and bronchial asthma. Arerugi 2008;57:1117-1123.
48. Bazzi MD, Sultan MA, Al Tassan N, Alanazi M, Al-Amri A, Al-Hajjaj MS, Al-Muhsen S, et al. Interleukin 17A and F and asthma in Saudi Arabia: gene polymorphisms and protein levels. J Investig Allergol Clin Immunol 2011;21:551-555.
49. Fujita J, Kawaguchi M, Kokubu F, Ohara G, Ota K, Huang SK, Morishima Y, et al. Interleukin-33 induces interleukin-17F in bronchial epithelial cells. Allergy 2012;67: 744-7450.
50. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol 1992;4:314-320.
51. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146: 3444-3451.
52. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998;160:3188-3193.
53. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010;10:225-235.
54. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type cytokines in IgE mediated allergy and asthma. Lung India 2010;27:66-71.
55. Shi YH, Shi GC, Wan HY, Jiang LH, Ai XY, Zhu HX, Tang W, et al. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma. Chin Med J (Engl) 2011;124:1951-1956.
56. Rudha Abbas SA. Comparative study of Interleukin-33 in Male with Chronic Obstructive Pulmonary Disease, Asthmatic Patients with Type2diabetes mellitus. International Journal of Innovative Research in Science, Engineering and Technology 2013;2:5947-5954.
57. Azazi EA, Elshora AE, Tantawy EA, Elsayd MA. Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients. Egyptian Journal of Chest Diseases and Tuberculosis 2013; 63:279-284.
58. Yang DX, Li N, Zhang XL, Wang Q. Serum interleukin 18 and 33 levels and its clinical significance in asthma patients. Zhonghua Jie He He Hu Xi Za Zhi 2012;35:493-496.
59. Préfontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010;125: 752-754.
60. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183:5094-5103.
61. Hamzaoui A, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. J Asthma 2013;50:803-809.
62. Mato N, Bando M, Yamasawa H, Hosono T, Mizushina Y, Sata M, Ohki G, et al. Role of IL-33 in bronchial asthma. Nihon Kokyuki Gakkai Zasshi 2010;48:419-425.
63. Dente FL, Carnevali S, Bartoli ML, Cianchetti S, Bacci E, Di Franco A, Vagaggini B, et al. Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients. Ann Allergy Asthma Immunol 2006;97:312-320.
64. Shute JK, Vrugt B, Lindley IJ, Holgate ST, Bron A, Aalbers R, Djukanović R. Free and complexed interleukin-8 in blood and bronchial mucosa in asthma. Am J Respir Crit Care Med 1997;155: 1877-1883.
65. Yamashita N, Tashimo H, Ishida H, Kaneko F, Nakano J, Kato H, Hirai K, et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol 2002;219: 92-97.
66. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 1997;156:1377-1383.
67. Almirall JJ, Páez I. Interpretation of spirometric tests in asthmatic patients with reduced forced vital capacity. J Investig Allergol Clin Immunol 1994;4:258-260.
68. Girdhar A, Kumar V, Singh A, Menon B, Vijayan VK. Systemic inflammation and its response to treatment in patients with asthma. Respir Care 2011;56:800-805.
69. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine 2009;46:7-11.
70. Hayashi H, Kawakita A, Okazaki S, Yasutomi M, Murai H, Ohshima Y. IL-17A/F modulates fibrocyte functions in cooperation with CD40-mediated signaling. Inflammation 2013;36: 830-838.
71. Tateno H, Nakamura H, Minematsu N, Nakajima T, Takahashi S, Nakamura M, Fukunaga K, et al. Plasma eotaxin level and severity of asthma treated with corticosteroid. Respir Med 2004;98: 782-790.
72. Friebe A, Volk HD. Stability of tumor necrosis factor alpha, interleukin 6, and interleukin 8 in blood samples of patients with systemic immune activation. Arch Pathol Lab Med 2008;132: 1802-1806.